BACKGROUND: Epidermal growth factor receptor (EGFR) intron 1 has a polymorphic region of CA repeats that is believed to be associated with increased EGFR expression, tumor aggressiveness, and worse survival in cancer patients. METHODS: A large population of pancreatic adenocarcinoma patients was investigated to evaluate this polymorphism as a potential prognostic marker of clinical outcome. Deoxyribonucleic acid obtained from 50 resected pancreatic adenocarcinomas and from 85 diagnostic endoscopic ultrasound-guided fine-needle aspiration procedures corresponding to patients with unresectable tumors was included. The correlation between CA repeat length and EGFR messenger ribonucleic acid levels was also examined. RESULTS: Analysis of the 135 patients revealed no correlation between EGFR intron 1 CA repeat length and tumor stage. There was no difference in overall patient survival when stratified by allele length. A correlation between EGFR intron 1 length and EGFR transcript and protein levels could not be established. CONCLUSIONS: The length of the EGFR intron 1 CA repeats does not correlate with levels of EGFR expression and cannot be used as marker of clinical prognosis in pancreatic cancer patients. 2010 Elsevier Inc. All rights reserved.
BACKGROUND:Epidermal growth factor receptor (EGFR) intron 1 has a polymorphic region of CA repeats that is believed to be associated with increased EGFR expression, tumor aggressiveness, and worse survival in cancerpatients. METHODS: A large population of pancreatic adenocarcinomapatients was investigated to evaluate this polymorphism as a potential prognostic marker of clinical outcome. Deoxyribonucleic acid obtained from 50 resected pancreatic adenocarcinomas and from 85 diagnostic endoscopic ultrasound-guided fine-needle aspiration procedures corresponding to patients with unresectable tumors was included. The correlation between CA repeat length and EGFR messenger ribonucleic acid levels was also examined. RESULTS: Analysis of the 135 patients revealed no correlation between EGFR intron 1 CA repeat length and tumor stage. There was no difference in overall patient survival when stratified by allele length. A correlation between EGFR intron 1 length and EGFR transcript and protein levels could not be established. CONCLUSIONS: The length of the EGFR intron 1 CA repeats does not correlate with levels of EGFR expression and cannot be used as marker of clinical prognosis in pancreatic cancerpatients. 2010 Elsevier Inc. All rights reserved.
Authors: H Buerger; F Gebhardt; H Schmidt; A Beckmann; K Hutmacher; R Simon; R Lelle; W Boecker; B Brandt Journal: Cancer Res Date: 2000-02-15 Impact factor: 12.701
Authors: Andrey Frolov; Santiago Chahwan; Michael Ochs; Juan Pablo Arnoletti; Zhong-Zong Pan; Olga Favorova; Jonathan Fletcher; Margaret von Mehren; Burton Eisenberg; Andrew K Godwin Journal: Mol Cancer Ther Date: 2003-08 Impact factor: 6.261
Authors: J A McKay; L J Murray; S Curran; V G Ross; C Clark; G I Murray; J Cassidy; H L McLeod Journal: Eur J Cancer Date: 2002-11 Impact factor: 9.162
Authors: N R Lemoine; C M Hughes; C M Barton; R Poulsom; R E Jeffery; G Klöppel; P A Hall; W J Gullick Journal: J Pathol Date: 1992-01 Impact factor: 7.996
Authors: S Boeck; A Jung; R P Laubender; J Neumann; R Egg; C Goritschan; U Vehling-Kaiser; C Winkelmann; L Fischer von Weikersthal; M R Clemens; T C Gauler; A Märten; S Klein; G Kojouharoff; M Barner; M Geissler; T F Greten; U Mansmann; T Kirchner; V Heinemann Journal: Br J Cancer Date: 2012-11-20 Impact factor: 7.640